应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02315 百奥赛图-B
耶稣受难节休市 04-02 16:08:21
63.500
+3.950
+6.63%
最高
65.050
最低
58.600
成交量
211.25万
今开
61.000
昨收
59.550
日振幅
10.83%
总市值
283.85亿
流通市值
70.49亿
总股本
4.47亿
成交额
1.32亿
换手率
1.90%
流通股本
1.11亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
港股百奥赛图-B涨超6%
每日经济新闻 · 04-02 11:43
港股百奥赛图-B涨超6%
百奥赛图-B午前涨超5% 与百奥赛图正式签署战略合作协定
新浪港股 · 04-02 11:39
百奥赛图-B午前涨超5% 与百奥赛图正式签署战略合作协定
异动解读 | 百奥赛图-B与四环医药达成战略合作,盘中大涨5.12%
异动解读 · 04-02 10:51
异动解读 | 百奥赛图-B与四环医药达成战略合作,盘中大涨5.12%
港股公告掘金 | 百奥赛图-B与四环医药(00460)达成战略合作 加速减重等多领域创新药研发
智通财经 · 04-02 08:59
港股公告掘金 | 百奥赛图-B与四环医药(00460)达成战略合作 加速减重等多领域创新药研发
智通港股早知道 | 美国执行载人绕月任务火箭发射升空 国际能源署署长:4月石油供应缺口将达到3月的两倍
智通财经 · 04-02 07:33
智通港股早知道 | 美国执行载人绕月任务火箭发射升空 国际能源署署长:4月石油供应缺口将达到3月的两倍
四环医药(00460)与百奥赛图(02315)达成战略合作 通过AI驱动的全人抗体研发平台加速减重等多领域创新药研发
智通财经 · 04-01 17:06
四环医药(00460)与百奥赛图(02315)达成战略合作 通过AI驱动的全人抗体研发平台加速减重等多领域创新药研发
净利跑出416%增速,百奥赛图-B(02315)迎来商业化兑现期
智通财经 · 03-30
净利跑出416%增速,百奥赛图-B(02315)迎来商业化兑现期
港股异动 | 百奥赛图-B(02315)涨超12% 全年纯利同比增超4倍 海外业务实现快速增长
智通财经 · 03-27
港股异动 | 百奥赛图-B(02315)涨超12% 全年纯利同比增超4倍 海外业务实现快速增长
百奥赛图-B(02315)合作伙伴NEOK Bio双抗ADC NEOK002获FDA IND许可,合作迈入关键里程碑
智通财经 · 03-26
百奥赛图-B(02315)合作伙伴NEOK Bio双抗ADC NEOK002获FDA IND许可,合作迈入关键里程碑
港股百奥赛图-B涨超12%
每日经济新闻 · 03-24
港股百奥赛图-B涨超12%
港股异动 | 百奥赛图-B(02315)涨超12% 与Moonlight Bio达成战略合作 去年纯利同比预增超四倍
智通财经 · 03-24
港股异动 | 百奥赛图-B(02315)涨超12% 与Moonlight Bio达成战略合作 去年纯利同比预增超四倍
百奥赛图宣布与Moonlight Bio达成战略合作,利用全人抗体分子库推进细胞疗法开发
美通社 · 03-23
百奥赛图宣布与Moonlight Bio达成战略合作,利用全人抗体分子库推进细胞疗法开发
百奥赛图-B盘中涨超7%
每日经济新闻 · 03-16
百奥赛图-B盘中涨超7%
港股异动 | 百奥赛图-B(02315)盘中涨超7% 预计全年纯利同比增超4倍 重磅合作项目顺利推进
智通财经 · 03-16
港股异动 | 百奥赛图-B(02315)盘中涨超7% 预计全年纯利同比增超4倍 重磅合作项目顺利推进
每日卖空追踪 | 百奥赛图-B 03月11日卖空量成交3500股,卖空比例为0.4%
市场透视 · 03-11
每日卖空追踪 | 百奥赛图-B 03月11日卖空量成交3500股,卖空比例为0.4%
百奥赛图-B盘中异动 股价大跌5.04%报56.500港元
市场透视 · 03-11
百奥赛图-B盘中异动 股价大跌5.04%报56.500港元
【IPO前哨】诺令生物闯港股:女博士带队,光环与商业化焦虑并存
港股解码 · 03-09
【IPO前哨】诺令生物闯港股:女博士带队,光环与商业化焦虑并存
百奥赛图-B盘中异动 急速跳水7.23%报50.700港元
市场透视 · 03-09
百奥赛图-B盘中异动 急速跳水7.23%报50.700港元
港股异动 | 生物技术板块走强,药捷安康暴涨35%,百奥赛图涨14%
老虎资讯综合 · 03-06
港股异动 | 生物技术板块走强,药捷安康暴涨35%,百奥赛图涨14%
港股异动 | 百奥赛图-B(02315)涨超8% 预计25年归母净利同比增超4.16倍 商业化提速打开成长空间
智通财经 · 03-06
港股异动 | 百奥赛图-B(02315)涨超8% 预计25年归母净利同比增超4.16倍 商业化提速打开成长空间
加载更多
公司概况
公司名称:
百奥赛图-B
所属市场:
SEHK
上市日期:
--
主营业务:
百奥赛图(北京)医药科技股份有限公司是一家主要基于自主开发的基因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务的中国公司。该公司利用其自主开发的“RenMice”全人源抗体和T细胞受体(TCR)小鼠平台针对人体内潜在药物靶点进行规模化药物发现与开发。该公司主要业务包括创新模式动物销售、临床前药理药效评价服务及抗体开发。该公司还提供基因编辑服务。该公司在中国国内市场及海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奥赛图-B","latestPrice":63.5,"timestamp":1775117301004,"preClose":59.55,"halted":0,"volume":2112500,"delay":0,"changeRate":0.06633081444164572,"floatShares":111000000,"shares":447000000,"eps":0.43,"marketStatus":"耶稣受难节休市","change":3.95,"latestTime":"04-02 16:08:21","open":61,"high":65.05,"low":58.6,"amount":132265980,"amplitude":0.108312,"askPrice":63.5,"askSize":3000,"bidPrice":63.2,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":0.429,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":1661961600000,"exchange":"SEHK","adjPreClose":59.55,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":1.359326530715589,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688796","market":"SH","secType":"STK","nameCN":"百奥赛图","latestPrice":103.5,"timestamp":1775113200000,"preClose":99,"halted":0,"volume":4273800,"delay":0,"premium":"-46.09"}},"requestUrl":"/m/hq/s/02315","defaultTab":"news","newsList":[{"id":"2624868522","title":"港股百奥赛图-B涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624868522","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624868522?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:43","pubTimestamp":1775101431,"startTime":"0","endTime":"0","summary":"每经AI快讯,4月2日,百奥赛图-B(02315.HK)涨超6%,截至发稿涨6.3%,报63.3港元,成交额5601.17万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693164980.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693164980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688796","BK4585","BK4588","VXUS","BK0216","02315","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624052499","title":"百奥赛图-B午前涨超5% 与百奥赛图正式签署战略合作协定","url":"https://stock-news.laohu8.com/highlight/detail?id=2624052499","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624052499?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:39","pubTimestamp":1775101140,"startTime":"0","endTime":"0","summary":" 百奥赛图-B盘中涨超6%,截至发稿,股价上涨5.29%,现报62.70港元,成交额5695.47万港元。 四环医药与百奥赛图正式签署战略合作协定。双方将依托百奥赛图领先的全人抗体开发平台,结合四环医药在药物开发、生产和商业化方面的深厚经验,围绕减重等多个疾病领域的创新药物研发开展合作与交流,推动优势互补与资源协同,建立长期、稳定的合作关系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-02/doc-inhtaqzu2025048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","688796","02315","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110004282","title":"异动解读 | 百奥赛图-B与四环医药达成战略合作,盘中大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110004282","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110004282?lang=zh_cn&edition=full","pubTime":"2026-04-02 10:51","pubTimestamp":1775098276,"startTime":"0","endTime":"0","summary":"百奥赛图-B(02315)今日盘中大涨5.12%,引发了市场的广泛关注。消息面上,百奥赛图-B与四环医药(00460)正式签署战略合作协议。根据协议,双方将基于优势互补与专业协同的原则,结合四环医药在药物开发、规模化生产及商业化方面的全产业链经验,以及百奥赛图业内领先的AI驱动全人抗体开发平台核心技术,在减重等多个高潜力疾病领域开展创新药物的联合研发工作。此次合作旨在建立长期稳定、互利共赢的关系,共同推动全球前沿创新药的研发落地与商业化布局。市场分析认为,这一战略合作增强了市场对百奥赛图-B未来在创新药研发领域增长潜力的信心,是推动其股价上涨的直接原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624251435","title":"港股公告掘金 | 百奥赛图-B与四环医药(00460)达成战略合作 加速减重等多领域创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2624251435","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624251435?lang=zh_cn&edition=full","pubTime":"2026-04-02 08:59","pubTimestamp":1775091553,"startTime":"0","endTime":"0","summary":"重大事项:百奥赛图-B(02315)与四环医药(00460)达成战略合作 加速减重等多领域创新药研发远东发展(00035)拟出售墨尔本丽思卡尔顿酒店49.9%权益大唐环境(01272)拟斥资约2457.41万元收购报废风电设备荣昌生物(09995):国家药监局批准双特异性抗体药物偶联物(双抗ADC)注射用RC288开展临床试验易生活控股(00223):与雅澳供应链启动AI数字供应链战略合作经营业绩","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588545490.SGD","BK1521","BK1610","LU0244354667.USD","LU0516422440.USD","LU0531970944.HKD","LU0979878070.USD","LU0348735423.USD","LU0259732245.USD","LU1880383440.USD","LU0348825331.USD","LU0871576103.HKD","SG9999015945.SGD","00460","LU1868837565.USD","LU0359201885.HKD","LU2249611893.SGD","LU1720050803.USD","BK1515","BK1600","LU0417516738.SGD","02315","LU2097828805.USD","BK1191","LU2097828631.EUR","BK1509","80175","LU1023057109.AUD","LU2399975544.HKD","LU0052750758.USD","LU1861214812.USD","LU2097828714.EUR","LU0594300419.USD","BK4585","BK1522","LU0819121731.USD","LU0588545904.SGD","LU2294711713.HKD","LU0269904917.USD","LU0823038988.USD","LU0856984785.SGD","LU1868837722.USD","LU2039709279.SGD","LU1868838027.USD","LU0320764599.SGD","LU0164865239.USD","BK4588","BK1593","LU0823039010.USD","LU2778985437.USD","LU0175139822.USD","LU0511384066.AUD","BK1161","LU0327786744.USD","LU0315178854.USD","LU0314109678.HKD","LU0469268626.HKD","BK1540","BYDDY","IE00BZ08YS42.EUR","LU0588546209.SGD","LU2153592121.USD","LU1303224171.USD","BK1589","LU0289961442.SGD","LU0594300179.USD","LU0348827113.USD","LU0593848301.USD","LU0054450605.USD","SG9999015986.USD","LU0359201612.USD","LU0828238088.HKD","LU1794554557.SGD","LU2097828557.USD","LU1808992512.USD","HYDD.SI","LU0561508036.HKD","LU1188198961.HKD","IE00BD6J9T35.USD","LU0084288322.USD","002594","BK1539","LU0143863198.USD","LU2476274308.USD","LU0289739343.SGD","SG9999014674.SGD","IE00B0JY6N72.USD","LU2476274720.SGD","LU0293314216.USD","BK0216","SG9999002828.SGD","IE00BZ08YT58.USD","LU1719994722.HKD","LU0650527681.SGD","LU0164872284.USD","LU0516423174.USD","LU1224444064.USD","LU1961090484.USD","LU0505663152.USD","LU0516422366.SGD","LU0214875030.USD","LU0449509016.USD","LU0143863784.USD","LU0634319403.HKD","BK1574","LU0819123356.HKD","LU0531971595.HKD","IE00BZ08YR35.GBP","LU1242518857.USD","LU0605514214.HKD","LU1282651121.HKD","GELYY","LU1251922891.USD","LU2097828474.EUR","LU0708995583.HKD","LU0254981946.USD","BK1124","LU2348774022.SGD","SG9999015952.SGD","EVS.SI","SG9999006514.SGD","SG9999001226.SGD","LU0588545730.USD","LU0543330566.HKD","LU0211977185.USD","LU0417516902.SGD","LU0823426480.USD","LU2360107325.USD","LU1242518931.SGD","LU0516422952.EUR","LU2506951792.HKD","LU0823414478.USD","LU1770034418.SGD","LU0289960550.SGD","LU0463099449.HKD","688796","BK1594","SG9999002463.SGD","BK1119","LU0540923850.HKD","LU1880383366.USD","LU1328277881.USD","LU0359202008.SGD","LU0865486749.SGD","LU1861219969.SGD","81211","LU0823426308.USD","LU0229945570.USD","LU0326950275.SGD","LU0307460666.USD","LU0509642566.USD","SG9999006597.SGD","BK1240","LU2449936058.SGD","LU0315179316.USD","LU0039217434.USD","LU0823414551.USD","LU0449515922.USD","LU0516423091.SGD","LU2357125470.USD","LU1282651048.USD","LU1813983027.USD","BK1582","LU0043850808.USD","LU0348805143.USD","LU0572944931.SGD","SG9999015978.USD","LU0165289439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624540176","title":"智通港股早知道 | 美国执行载人绕月任务火箭发射升空 国际能源署署长:4月石油供应缺口将达到3月的两倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2624540176","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624540176?lang=zh_cn&edition=full","pubTime":"2026-04-02 07:33","pubTimestamp":1775086385,"startTime":"0","endTime":"0","summary":"美国执行载人绕月任务火箭发射升空当地时间4月1日傍晚,美国航空航天局新一代登月火箭“太空发射系统”从佛罗里达州肯尼迪航天中心发射升空,执行“阿耳忒弥斯2号”载人绕月任务。这是美国自1972年以来首次载人飞向月球。据知情人士透露,这家卫星制造与火箭发射公司已以保密方式递交上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06681","LU1152091168.USD","BK1600","BK4570","BK1593","03759","BK4585","02256","02315","BK1116","BK1194","LU1993786604.SGD","BK1191","BK1576","BK1141","300750","688796","LU1152091754.HKD","03750","300759","XOP","01857","LU0067412154.USD","LU1008478684.HKD","BK4588","LU1960683339.HKD","LU0880133367.SGD","BK1161","00460","LU1807302812.USD","BK1610","BK1515","XLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624960675","title":"四环医药(00460)与百奥赛图(02315)达成战略合作 通过AI驱动的全人抗体研发平台加速减重等多领域创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2624960675","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624960675?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:06","pubTimestamp":1775034361,"startTime":"0","endTime":"0","summary":"智通财经APP讯,四环医药 发布公告,集团与百奥赛图(北京)医药科技股份有限公司正式签署战略合作协定。双方将立足优势互补与专业协同的合作原则,凭借集团在药物开发、规模化生产及商业化环节的全产业链成熟经验,结合百奥赛图业内领先的AI驱动全人抗体开发平台核心技术,在减重等多个高潜力疾病领域开展创新药物联合研发工作,建立长期稳定、互利共赢的合作关系,共同推动全球前沿创新药的研发落地与商业化布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","AIPO","AGIX","00460","BK1515","BK1191","BK0216","06978","688796","BK1600","02315","159992","CHAT","BK1161","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623612963","title":"净利跑出416%增速,百奥赛图-B(02315)迎来商业化兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2623612963","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623612963?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:06","pubTimestamp":1774832793,"startTime":"0","endTime":"0","summary":"2026年,创新药板块迎来多重利好共振,行业回暖态势明确。2025年,公司模式动物业务收入6.22亿元,同比增长近60%,毛利率超80%,持续贡献稳定现金流。2025年,百奥赛图抗体开发业务实现收入3.32亿元,毛利率达86%;累计签署超350项合作协议,其中2025年就新增150余项。短期业绩利好催化股价上行,叠加长期价值逐步显现,百奥赛图凭借其创新技术、稀缺的商业模式与全球新药研发体系中的有利卡位,有望率先受益于行业景气度回升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BK1161","02315","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622045816","title":"港股异动 | 百奥赛图-B(02315)涨超12% 全年纯利同比增超4倍 海外业务实现快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622045816","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622045816?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:39","pubTimestamp":1774579145,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B涨超12%,截至发稿,涨11.99%,报60.25港元,成交额7808.72万港元。消息面上,百奥赛图发布2025年度业绩,公司实现营业收入13.79亿元,同比增长40.63%,归母净利润1.73亿元,同比增长416.37%,扣非净利润1.16亿元,同比增长405.39%。值得关注的是,百奥赛图全球化布局成果卓越,2025年海外收入占比近70%,服务网络覆盖美国,欧洲和亚太市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02315","BK0216","BK4588","BK4585","VXUS","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622986952","title":"百奥赛图-B(02315)合作伙伴NEOK Bio双抗ADC NEOK002获FDA IND许可,合作迈入关键里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2622986952","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622986952?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:35","pubTimestamp":1774535741,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百奥赛图-B 发布公告,本公司合作伙伴NEOK Bio, Inc.近日获得美国食品药品监督管理局对其在研新药NEOK002的新药临床试验申请批准。NEOK Bio计划于2026年第二季度启动I期临床试验,并预计于2027年公布初步临床数据。此次IND获批标志着NEOK002项目取得重要里程碑进展。NEOK002基于百奥赛图自主开发并于2024年对外授权的双特异性抗体构建,由NEOK Bio进一步推进 ADC药物开发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419949.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","IND","688796","BK4585","LABU","ADC","BK1161","02315","BK4080","BK4588","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621051654","title":"港股百奥赛图-B涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621051654","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621051654?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:14","pubTimestamp":1774336484,"startTime":"0","endTime":"0","summary":"每经AI快讯,3月24日,百奥赛图-B(02315.HK)涨超12%,截至发稿,涨12.14%,报54.5港元,成交额1.6亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682503514.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682503514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","VXUS","688796","BK4585","BK1161","02315","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621105609","title":"港股异动 | 百奥赛图-B(02315)涨超12% 与Moonlight Bio达成战略合作 去年纯利同比预增超四倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2621105609","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621105609?lang=zh_cn&edition=full","pubTime":"2026-03-24 14:58","pubTimestamp":1774335519,"startTime":"0","endTime":"0","summary":"消息面上,3月23日,百奥赛图宣布与总部位于西雅图、深耕前沿细胞疗法的生物技术公司Moonlight Bio, Inc.达成战略合作协议。根据协议条款,百奥赛图将提供针对治疗靶点的全人抗体分子,Moonlight Bio将负责相关细胞疗法的临床前开发工作。此外,百奥赛图此前发布2025年度业绩快报,预计2025年营业收入约为13.79亿元,同比增长40.63%;实现归属于公司所有者的净利润人民币1.73亿元,同比增长416.37%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","688796","BK1161","BK4585","02315","VXUS","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621765703","title":"百奥赛图宣布与Moonlight Bio达成战略合作,利用全人抗体分子库推进细胞疗法开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2621765703","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621765703?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:00","pubTimestamp":1774267200,"startTime":"0","endTime":"0","summary":"北京2026年3月23日 /美通社/ -- 百奥赛图(北京)医药科技股份有限公司,一家以创新技术驱动新药研发的国际性生物技术公司,今日宣布与总部位于西雅图、深耕前沿细胞疗法的生物技术公司Moonlight Bio, Inc.达成战略合作协议。此次战略合作将利用我们自主研发的货架型全人抗体库,加速针对难治性癌症的创新细胞疗法的开发。\" 根据协议条款,百奥赛图将提供针对治疗靶点的全人抗体分子,Moonlight Bio将负责相关细胞疗法的临床前开发工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4916326_ZH16326_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["688796","02315","BK0216","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619458913","title":"百奥赛图-B盘中涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619458913","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619458913?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:00","pubTimestamp":1773648022,"startTime":"0","endTime":"0","summary":"每经AI快讯,3月16日,百奥赛图-B(02315.HK)盘中涨超7%,截至发稿涨5.9%,报57.45港元,成交额3372.77万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603163673093149.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603163673093149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02315","688796","BK1161","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619430152","title":"港股异动 | 百奥赛图-B(02315)盘中涨超7% 预计全年纯利同比增超4倍 重磅合作项目顺利推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2619430152","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619430152?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:47","pubTimestamp":1773647247,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B(02315)盘中涨超7%,截至发稿,涨5.9%,报57.45港元,成交额3372.77万港元。消息面上,百奥赛图此前发布2025年业绩快报,初步会计数据显示,该公司2025年营收约13.79亿元,实现归母净利1.73亿元,分别同比增长40.63%、416.37%。此外,公司授权IDEAYA的B7H3/PTK7 ADC候选药物IDE034完成1期临床试验首例患者入组,IDEAYA将向公司支付500万美元里程碑付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BK4588","BK1161","02315","BK4585","688796","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618891294","title":"每日卖空追踪 | 百奥赛图-B 03月11日卖空量成交3500股,卖空比例为0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618891294","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618891294?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217829,"startTime":"0","endTime":"0","summary":"百奥赛图-B北京时间03月11日,跌5.04%,卖空量成交3500股,较上一交易日减少92.05%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163358a460b6a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163358a460b6a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618912969","title":"百奥赛图-B盘中异动 股价大跌5.04%报56.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618912969","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618912969?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:50","pubTimestamp":1773193844,"startTime":"0","endTime":"0","summary":"2026年03月11日早盘09时50分,百奥赛图-B股票出现异动,股价大幅跳水5.04%。截至发稿,该股报56.500港元/股,成交量17万股,换手率0.15%,振幅6.55%。资金方面,该股资金流入213.028万港元,流出669.32万港元。百奥赛图-B股票所在的生物技术行业中,整体跌幅为0.48%。其相关个股中,中慧生物-B、永泰生物-B、乐普生物-B涨幅较大,振幅较大的相关个股有中慧生物-B、映恩生物-B、百奥赛图-B,振幅分别为13.92%、8.53%、6.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311095044a45fcf97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311095044a45fcf97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618257086","title":"【IPO前哨】诺令生物闯港股:女博士带队,光环与商业化焦虑并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2618257086","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618257086?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:48","pubTimestamp":1773046080,"startTime":"0","endTime":"0","summary":"诺令生物的核心产品iNOwill,打破了这一惯例。诺令生物对此野心勃勃,未来计划构建以iNO为核心的综合生态系统、持续拓宽心肺诊疗产品管线,并积极扩充全球业务版图。诺令生物的商业化表现,未能匹配技术领域的突破。截至2025年9月底,公司账上现金及现金等价物仅剩3001.8万元,另外还有定期存款1.41亿元。截至2025年9月底,公司负债总额达5.57亿元,负债净额达3.22亿元。对于投资者而言,诺令生物的稀缺性毋庸置疑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650512722&idx=2&sn=c7e7e4c704805537353daff787c53659&chksm=f260e83dc517612b6f939ca941b3bfd4d46c262d5c478ce0ada2eeb5d08af635fe6cafb970d8#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1161","BK1141","02627","BK1574","02315","01875","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618676116","title":"百奥赛图-B盘中异动 急速跳水7.23%报50.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618676116","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618676116?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:32","pubTimestamp":1773019967,"startTime":"0","endTime":"0","summary":"2026年03月09日早盘09时32分,百奥赛图-B股票出现异动,股价大幅下挫7.23%。截至发稿,该股报50.700港元/股,成交量6.15万股,换手率0.06%,振幅3.66%。资金方面,该股资金流入62.01万港元,流出147.988万港元。最近的财报数据显示,该股实现营业收入6.81亿港元,净利润5,263.34万港元,每股收益0.13港元,毛利5.07亿港元,市盈率633.56倍。百奥赛图-B股票所在的生物技术行业中,整体跌幅为2.20%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030909324795458d25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030909324795458d25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151451437","title":"港股异动 | 生物技术板块走强,药捷安康暴涨35%,百奥赛图涨14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151451437","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151451437?lang=zh_cn&edition=full","pubTime":"2026-03-06 11:32","pubTimestamp":1772767952,"startTime":"0","endTime":"0","summary":"圣诺医药涨超11%,荣昌生物、基石药业涨超8%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5137f1e9d165d819bc52e4abac894dbc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315","02617","02616","02257","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617068725","title":"港股异动 | 百奥赛图-B(02315)涨超8% 预计25年归母净利同比增超4.16倍 商业化提速打开成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2617068725","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617068725?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:27","pubTimestamp":1772764049,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B涨超8%,截至发稿,涨8.15%,报48.86港元,成交额1920.34万港元。消息面上,近日,百奥赛图-B发布2025年度业绩快报,预计集团2025年营业收入约为13.79亿元同比增长40.63%;实现归属于本公司所有者的净利润人民币1.73亿元,同比增长416.37%;实现归属于本公司所有者的扣除非经常性损益的净利润人民币1.16亿元,同比增长405.39%。该行认为,随着授权项目数增加及临床进展推进,抗体开发业务业绩弹性将加速释放,打开公司长期成长空间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","VXUS","BK1161","BK4585","BK0216","BK4588","02315","688796"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bbctg.com.cn","stockEarnings":[{"period":"1week","weight":0.1803},{"period":"1month","weight":0.3745},{"period":"3month","weight":0.8279},{"period":"6month","weight":1.3108},{"period":"1year","weight":3.1612},{"period":"ytd","weight":0.7989}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"百奥赛图(北京)医药科技股份有限公司是一家主要基于自主开发的基因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务的中国公司。该公司利用其自主开发的“RenMice”全人源抗体和T细胞受体(TCR)小鼠平台针对人体内潜在药物靶点进行规模化药物发现与开发。该公司主要业务包括创新模式动物销售、临床前药理药效评价服务及抗体开发。该公司还提供基因编辑服务。该公司在中国国内市场及海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.018702},{"month":2,"riseRate":0.75,"avgChangeRate":0.087225},{"month":3,"riseRate":0.5,"avgChangeRate":0.15364},{"month":4,"riseRate":0.5,"avgChangeRate":-0.013128},{"month":5,"riseRate":0.666667,"avgChangeRate":0.14952},{"month":6,"riseRate":0.333333,"avgChangeRate":0.011218},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.033427},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.055975},{"month":9,"riseRate":0.666667,"avgChangeRate":0.092895},{"month":10,"riseRate":0.25,"avgChangeRate":-0.096483},{"month":11,"riseRate":0.5,"avgChangeRate":0.009059},{"month":12,"riseRate":0.5,"avgChangeRate":0.137663}],"exchange":"SEHK","name":"百奥赛图-B","nameEN":"BIOCYTOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥赛图-B(02315)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥赛图-B,02315,百奥赛图-B股票,百奥赛图-B股票老虎,百奥赛图-B股票老虎国际,百奥赛图-B行情,百奥赛图-B股票行情,百奥赛图-B股价,百奥赛图-B股市,百奥赛图-B股票价格,百奥赛图-B股票交易,百奥赛图-B股票购买,百奥赛图-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥赛图-B(02315)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}